Our mission is to develop novel biopharmaceuticals for the relief, prevention, and treatment of chronic pain and hearing loss
Neuropathic Pain and Hearing Loss
HB-086 is in late preclinical development for Neuropathic Pain. Target indications are Chemotherapy-Induced Peripheral Neuropathy (CIPN) and trigeminal neuralgia.
HB-097 is in preclinical development for sensorineural hearing loss. The target indication is Ototix Hearing Loss.
14 October 2021
Hoba Therapeutics has been selected by The European Commission’s European Innovation Council (EIC) as a start-up champion. Hoba will receive grant funding and qualifies for further equity investment from EIC Accelerator.
August 2019 - New Publication
Antihyperalgesic effects of Meteorin in the rat chronic constriction injury model: a replication study.
October 2018 - Grand Solution Funding (IFD)
Danish Hoba Therapeutics and a consortium of national and international partners have secured the ongoing development of the drug candidate HB-086 for treatment of neuropathic pain with an investment from Innovation Fund Denmark (IFD) of DKK18.4M (≈€2.5M), and thereby a major step towards clinical trials